My ePortfolio Register   

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.06.17
Views: 2073
Rating:

Dr Yi Lin - Mayo Clinic, Rochester, USA

Dr Lin speaks with ecancer at EHA 2017 about clinical and biologic outcomes in patients with refractory aggressive Non-Hodgkin Lymphoma (NHL) treated with CAR T cell therapy.

She notes an objective response rate of 82% and a complete response rate well about historic control rates.

Dr Lin notes cytokine release syndrome and neurologic events, common to CAR T therapies, were reversible, and that 99% of patients were able to receive the treatment.

Read the news story and watch the press conference for more.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence